Pfizer drops two Phase III compounds

Pfizer (NYSE:PFE) discontinued development of a pair of compounds in Phase III testing after data showed they were unlikely to provide "meaningful benefit" to patients beyond the current standard of care. Esreboxetine, an oral selective norepinephrine reuptake inhibitor, was in testing for fibromyalgia. PD 332,334, which targeted the alpha 2 delta subunit of a voltage-dependent calcium channel, was in development for generalized anxiety disorder (GAD). ...